Northwell Health opens Center for Bioelectronic Medicine
LA CROSSE, Wis. (WLAX/WEUX) – Northwell Health has been a pioneer in the bioelectronic medicinal research field for decades. Finally, they were able to open a clinical Center for Bioelectronic Medicine in Manhasset, New York. Now, they are looking for people interested in bioelectronic medicine clinical trials, like studies to evaluate vagus nerve stimulation.
President and CEO of Northwell, Michael J. Dowling, says, 'Northwell Health prides itself on offering patients innovative treatment. Bioelectronic medicine has shown benefit to patients in clinical trials, and with the development and expansion of the field, we have an opportunity to offer this cutting-edge treatment to our patients. Northwell's Center for Bioelectronic Medicine is a unique destination where doctors, scientists and patients will explore and potentially benefit from today's medical advancements.'
The scientific foundation of bioelectronic medicine stems from research conducted by , president and CEO of , Northwell's home of medical research, and author of the new book – . For nearly four decades, Dr. Tracey and collaborators published their discoveries about a link between the brain, immune system, and inflammation and whether or not their connection could be modulated through technology and electrical signals, like vagus nerve stimulation. Today, bioelectronic medicine clinical trials are conducted at Northwell and around the world. In 2023, Northwell was a site for the SetPoint Medical RESET-RA study, which evaluated a novel treatment option for rheumatoid arthritis (RA) using neuroimmune modulation, a therapy that uses electrical stimulation to modulate functions of the immune system.
Dawn Steiner, one of the RESET-RA trial participants, has firsthand experience with the debilitating effects of RA. For more than a decade, the 58-year-old speech and language pathologist from Massapequa, NY, felt excruciating pain that often left her bedridden. An avid Mets fan and concertgoer, Dawn found herself unable to enjoy the things she loved – or even conduct everyday tasks, like brushing her teeth or tying her shoes – because of her RA flare-ups or her medication side effects. Over the years, she tried more than eight biological RA medications that often didn't relieve her symptoms and caused her to feel troubling side effects. After seeing family and friends benefit from enrolling in clinical trials for other conditions, Dawn enrolled in the SetPoint Medical trial, and today, many of her symptoms are relieved.
'A year after receiving this therapy, I feel as good as I did before my RA diagnosis – like a different person. I feel better, and I'm able to just feel healthy and do all the things that make me happy without those awful, awful medications,' Steiner said. 'To the researchers, thank you! I'm so glad you looked into a different type of technology. From my perspective, this is the future of rheumatoid arthritis treatment.'
The new Center will aim to connect participants like Dawn to bioelectronic medicine clinical trials. Current bioelectronic medicine trials underway at Northwell include treatments for pediatric inflammatory bowel disease, methods to stop excessive bleeding, treatments for post-traumatic stress disorders and brain implant applications to reverse paralysis.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 hours ago
- Business Wire
Sonoma Biotherapeutics Announces Poster Presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)-- Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress, taking place in Barcelona on June 11-14, 2025. Details of the presentations are as follows: Poster Presentation Details: Title: 'REGULATE-RA: A Phase 1 Study of CAR-Treg Cells Targeting Citrullinated Proteins in Refractory Rheumatoid Arthritis: Interim Report of Patient Characteristics and Safety' Presenting Author: Sarah K. Baxter, MD, PhD Poster number: POS0034 Session: Clinical Poster Tours: Difficult to treat Rheumatoid Arthritis Date/ Time: Location: Poster Tour IV About Sonoma Biotherapeutics Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information, visit and follow on X, formerly Twitter, and LinkedIn.
Yahoo
a day ago
- Yahoo
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
VALENCIA, Calif., June 04, 2025--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced the appointment of Tyler Binney to its Board of Directors. With a career built around scaling disruptive MedTech platforms, Binney brings over two decades of commercial leadership experience that will be instrumental to SetPoint's mission to deliver a new treatment alternative to patients with autoimmune conditions, including rheumatoid arthritis (RA). "Tyler has a strong track record of building successful commercial organizations and delivering sustained growth in new markets," said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. "His experience bringing novel, category-creating technologies to market will be an incredible asset to our team as we work to provide patients with access to our innovative neuroimmune modulation platform." With over 20 years of proven leadership experience in the medical device industry, Mr. Binney most recently served as President and Chief Executive Officer of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and General Manager of the Interventional Urology Business Unit at Teleflex, and as Vice President of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex. "What SetPoint is doing in the field of neuroimmune modulation is truly groundbreaking," said Tyler Binney. "This team is on the verge of transforming the treatment of chronic autoimmune conditions, and I look forward to contributing my experience as they accelerate their strategy to commercialize this platform technology." About SetPoint Medical SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical's platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit View source version on Contacts Emma YangHealth+Commercemedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
a day ago
- Business Wire
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
VALENCIA, Calif.--(BUSINESS WIRE)-- SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced the appointment of Tyler Binney to its Board of Directors. With a career built around scaling disruptive MedTech platforms, Binney brings over two decades of commercial leadership experience that will be instrumental to SetPoint's mission to deliver a new treatment alternative to patients with autoimmune conditions, including rheumatoid arthritis (RA). 'Tyler has a strong track record of building successful commercial organizations and delivering sustained growth in new markets,' said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. 'His experience bringing novel, category-creating technologies to market will be an incredible asset to our team as we work to provide patients with access to our innovative neuroimmune modulation platform.' With over 20 years of proven leadership experience in the medical device industry, Mr. Binney most recently served as President and Chief Executive Officer of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and General Manager of the Interventional Urology Business Unit at Teleflex, and as Vice President of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex. 'What SetPoint is doing in the field of neuroimmune modulation is truly groundbreaking,' said Tyler Binney. 'This team is on the verge of transforming the treatment of chronic autoimmune conditions, and I look forward to contributing my experience as they accelerate their strategy to commercialize this platform technology.' About SetPoint Medical SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical's platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit